ROCKVILLE, Md.--(BUSINESS WIRE)--BioFactura, Inc. was awarded a US patent covering the core technologies of its proprietary StableFastTM Biomanufacturing Platform. The US Patent and Trademark Office allowed 32 claims broadly covering composition of matter, methods, commercial kits, and media formulations. StableFastTM was commercially launched earlier this year. The Company is actively marketing the system to companies developing biopharmaceuticals including novel compounds and biosimilars with a focus on therapeutic monoclonal antibodies.
“This patent represents years of innovation and development by the BioFactura team that includes the Company's original founders,” said Darryl Sampey, BioFactura’s President and CEO. “I’d also like to acknowledge the excellent work of our intellectual property legal team at Womble Carlyle. We are proud that the USPTO has allowed such a broad set of claims, and we look forward to bringing the StableFastTM platform to a range of clients in the private and government sectors seeking to develop and manufacture tomorrow’s lifesaving drugs.”
BioFactura (Rockville, MD) offers companies developing monoclonal antibody-based drugs shorter time-to-market, reduced costs, and high potency/fidelity drug candidates through the application of its proprietary Rapid Human Antibody Generation (RHAGeTM) System.